Editas Medicine, Inc.
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301 (NCT06363760) | Editas Medicine, Inc. | 2024-06-17 |
| EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) (NCT05444894) | Editas Medicine, Inc. | 2022-04-29 |
| A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) (NCT04853576) | Editas Medicine, Inc. | 2021-05-04 |
| Single Ascending Dose Study in Participants With LCA10 (NCT03872479) | Editas Medicine, Inc. | 2019-09-26 |
| Natural History Study of CEP290-Related Retinal Degeneration (NCT03396042) | Editas Medicine, Inc. | 2017-12-17 |
Track Editas Medicine, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.